---
title: "MPCSH plans to raise no more than 532 million yuan through a private placement to its controlling shareholder"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255334813.md"
description: "According to the Zhitong Finance APP, MPCSH has announced a plan to issue A-shares to specific targets, with the issuer being the company's controlling shareholder, Maoming Port, which will subscribe to the shares in cash in RMB. The total amount of funds raised from this specific issuance will not exceed RMB 532 million (including the principal), and after deducting relevant issuance costs, all funds will be used to replenish working capital"
datetime: "2025-08-31T08:14:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255334813.md)
  - [en](https://longbridge.com/en/news/255334813.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255334813.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/255334813.md) | [繁體中文](https://longbridge.com/zh-HK/news/255334813.md)


# MPCSH plans to raise no more than 532 million yuan through a private placement to its controlling shareholder

According to the Zhitong Finance APP, MPCSH (000637.SZ) has announced a plan to issue A-shares to specific targets, with the issuer being the company's controlling shareholder, Maoming Port, which will subscribe to the shares in cash in RMB. The total amount of funds raised from this specific issuance will not exceed RMB 532 million (including the principal), and after deducting relevant issuance costs, all funds will be used to replenish working capital

### 相关股票

- [MPCSH (000637.CN)](https://longbridge.com/zh-CN/quote/000637.CN.md)

## 相关资讯与研究

- [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-CN/news/278445287.md)
- [Bessent, on safe passage of ships in Strait of Hormuz, says U.S. is on track to get this solved](https://longbridge.com/zh-CN/news/278171367.md)
- [13:46 ETNanchang Optoelectronic Industry Cluster brilla en ISLE 2026](https://longbridge.com/zh-CN/news/278597263.md)
- [Kainova Therapeutics reports positive phase 1 results for DT‑9081 in advanced solid tumours](https://longbridge.com/zh-CN/news/278526333.md)
- [Vinachem diversifies fertiliser raw material supply](https://longbridge.com/zh-CN/news/278532872.md)